{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:39:38Z","timestamp":1789061978173,"version":"build-2803163510"},"reference-count":25,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2023,5,28]]},"DOI":"10.1080\/14737167.2023.2196408","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T09:53:11Z","timestamp":1680083591000},"page":"579-589","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness of acalabrutinib regimens in treatment-na\u00efve chronic lymphocytic leukemia in the United States"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"first","affiliation":[{"name":"Department of Haematology, Leeds Teaching Hospital NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Genovez","sequence":"additional","affiliation":[{"name":"Health Economics & Market Access, Amaris Consulting, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Genestier","sequence":"additional","affiliation":[{"name":"Amaris Consulting, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie","family":"Ryan","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Liljas","sequence":"additional","affiliation":[{"name":"Oncology Market Access & Pricing, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Gaitonde","sequence":"additional","affiliation":[{"name":"Oncology Market Access & Pricing, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"cit0001","unstructured":"American Cancer Society. What is chronic lymphocytic leukemia? 2018. Available at: https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/about\/what-is-cll.html. Accessed: Nov 17, 2022."},{"key":"cit0002","unstructured":"American Society of Clinical Oncology. Leukemia - chronic lymphocytic - CLL: statistics. 2021. Available at: https:\/\/www.cancer.net\/cancer-types\/leukemia-chronic-lymphocytic-cll\/statistics. Accessed: Nov 17, 2022."},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3855"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"cit0005","unstructured":"National Cancer Institute. SEER cancer stat facts: leukemia - chronic lymphocytic leukemia. 2022. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed: Nov 17, 2022."},{"key":"cit0006","volume-title":"Calquence [package insert]","year":"2022"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00845-x"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.569500"},{"key":"cit0011","unstructured":"Institute for Clinical and Economic Review. ICER\u2019s reference case for economic evaluations: principles and rationale. 2020. Available at: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Reference_Case_013120.pdf. Accessed: Nov 17, 2022."},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"cit0013","unstructured":"Latimer N NICE DSU technical support document 14. Survival analysis for economic evaluations alongside clinical trials \u2013 extrapolation with patient-level data Sheffield: NICE decision support Unit; 2013 [updated Mar 2013;Aug 3, 2020]. Available at: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. Accessed: Nov 17, 2022."},{"key":"cit0014","first-page":"1","volume":"69","author":"Arias E","year":"2020","journal-title":"Natl Vital Stat Rep"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146570"},{"key":"cit0016","unstructured":"National Institute for Health and Care Excellence. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. 2019. Available at: www.nice.org.uk\/guidance\/ta561. Accessed: Nov 17, 2022."},{"key":"cit0017","unstructured":"IBM Micromedex RED BOOK: iBM Watson Health; 2022 [Jul 8, 2022]. Available at: https:\/\/www.ibm.com\/products\/micromedex-red-book. Accessed: Nov 17, 2022."},{"key":"cit0018","unstructured":"Centers for Medicare and Medicaid Services. Search the Physician Fee Schedule. 2022. Available at: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search. Accessed: Nov 17, 2022."},{"key":"cit0019","volume-title":"Annual Meeting and Exposition of the American Society of Hematology","author":"Davids MS"},{"key":"cit0020","unstructured":"Agency for Healthcare Research and Quality. Healthcare cost and utilization project. 2022. Available at: https:\/\/hcupnet.ahrq.gov\/#setup. Accessed: Nov 17, 2022."},{"key":"cit0021","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Care Excellence. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. 2016. Available at: https:\/\/www.nice.org.uk\/guidance\/ta403. Accessed: Nov 17, 2022.","DOI":"10.1016\/S1470-2045(16)30435-1"},{"key":"cit0022","unstructured":"National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. Available at: www.nice.org.uk\/guidance\/ng115. Accessed: Nov 17, 2022."},{"key":"cit0023","unstructured":"Health Resources & Services Administration. Consumer Price Index (CPI) for medical care. 2021. Available at: https:\/\/www.hrsa.gov\/get-health-care\/affordable\/hill-burton\/cpi.html. Accessed: Nov 17, 2022."},{"key":"cit0024","unstructured":"Organisation for Economic Co-operation and Development. Prices and purchasing power parities (PPP). 2022. Available at: https:\/\/www.oecd.org\/sdd\/prices-ppp\/. Accessed: Nov 17, 2022."},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137688"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2023.2196408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T17:41:32Z","timestamp":1683135692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2023.2196408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,28]]}},"alternative-id":["10.1080\/14737167.2023.2196408"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2023.2196408","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}